Barclays PLC Acquires 63,702 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID)

Barclays PLC boosted its holdings in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 311.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,175 shares of the company’s stock after purchasing an additional 63,702 shares during the quarter. Barclays PLC owned about 0.12% of Ovid Therapeutics worth $98,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in OVID. XTX Topco Ltd boosted its stake in Ovid Therapeutics by 46.2% during the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after purchasing an additional 12,076 shares during the period. FMR LLC boosted its stake in Ovid Therapeutics by 1,907.4% during the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after purchasing an additional 47,723 shares during the period. Verition Fund Management LLC bought a new stake in Ovid Therapeutics during the 3rd quarter valued at approximately $88,000. Assenagon Asset Management S.A. bought a new stake in Ovid Therapeutics during the 3rd quarter valued at approximately $102,000. Finally, BNP Paribas Financial Markets raised its holdings in Ovid Therapeutics by 4,128.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after acquiring an additional 215,189 shares in the last quarter. Institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Trading Up 1.0 %

Shares of OVID opened at $0.71 on Friday. Ovid Therapeutics Inc. has a 1 year low of $0.68 and a 1 year high of $4.10. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $1.06. The stock has a market cap of $50.40 million, a PE ratio of -1.51 and a beta of 0.34.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Tuesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.15 million. On average, sell-side analysts predict that Ovid Therapeutics Inc. will post -0.4 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a report on Wednesday, December 4th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $4.04.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.